Novo Nordisk
75 Hayden Avenue
Lexington
MA
02421
United States
Tel: 617-612-6200
Website: https://www.novonordisk-us.com/
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.
Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.
CONNECT
Novo Nordisk is its people. We rely on the diversity of perspectives from colleagues all around the world. Our forward thinking, supported by careers that are as dynamic as we are, makes Novo Nordisk a great place to be and be from. This is your moment. Here we don’t stand still, we never give up – we make an impact. We’re trusted to have the courage. Together, we make it happen. To learn more, visit us at https://www.novonordisk-us.com/careers/find-a-job.html
1312 articles about Novo Nordisk
-
Novo Nordisk A/S - Share Repurchase Programme
5/27/2008
-
Neose Technologies, Inc. Announces Two Abstracts on GlycoPEGylated Factor VIIa Accepted for Presentation at the Hemophilia 2008 World Congress
5/27/2008
-
Novo Nordisk A/S Release: New Studies Showed FlexPen(R) Was Superior to SoloSTAR(R) in Dose Accuracy
5/20/2008
-
Novo Nordisk A/S - Share Repurchase Programme
5/19/2008
-
Neose Technologies, Inc. Receives Milestone Payment from Novo Nordisk A/S on Factor IX Program
5/19/2008
-
BioSpace Launches 6th Edition of Bio NC(TM) Hotbed Campaign
5/8/2008
-
Novo Nordisk A/S - 1st Quarter Results
4/30/2008
-
Aradigm Corporation Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx(R) Insulin Diabetes Management System (iDMS)
4/30/2008
-
Novo Nordisk A/S - Treasury Stock
4/28/2008
-
Novo Nordisk A/S to Expand West Windsor HQ; Intends to Add 400 Jobs
4/25/2008
-
Novo Nordisk A/S - Share Repurchase Programme
4/7/2008
-
Novo Nordisk A/S -- Treasury Stock
4/2/2008
-
Medarex, Inc. to Receive Milestone Payment from Novo Nordisk A/S
3/31/2008
-
Novo Nordisk A/S Release: FDA Approves NovoLog(R) for Use in Insulin Pumps by Children and Adolescents
3/18/2008
-
Novo Nordisk A/S - Share Repurchase Programme
3/17/2008
-
Novo Nordisk A/S Expands U.S. Headquarters in New Jersey; Adds New Jobs
3/5/2008
-
Novo Nordisk A/S Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
2/19/2008
-
Novo Nordisk A/S Files Annual Report with the SEC
2/13/2008
-
Neose Technologies, Inc. Receives Milestone Payment from Novo Nordisk A/S on Factor VIII Program
2/6/2008
-
Novo Nordisk A/S Increased Net Profit by 32% in 2007
1/31/2008